Lots of fud out there and negative view of this court

New Post Public Reply Private Reply Replies (1) Message Board
onestepahead
814
Lots of fud out there and negative view of this court case/bomd

Not my words below but of another investor and i agree with their analysts of whats really going on.
Cytodyn IS seeking damages against Amarex for harm to its clinical trial program and business reputation through arbitration. Damages currently being sought against Amarex could result in an enormous monetary sum paid to Cytodyn. There may be additional findings pertaining to damages after the audit is conducted which may be filed in court in the event of Amarex's gross negligence or willful misconduct. Gross negligence or willful misconduct is an exception to MSA 9.3 Limitation of Liability and Damage (which we both agree on).

I respectfully disagree with your point below on damages and likelihood and potential outcome of reaching a successful settlement:

Your quote: "Incidentally, the only side claiming monetary damages is Amarex who says they are owed $14 million. So any settlement would be Cytodyn agreeing to pay them, not the other way around.)"

From the court filings:

"In that arbitration, CytoDyn alleges that it has overpaid Amarex for work that was not properly performed and it is seeking damages from Amarex for harm to its clinical trial program and business reputation."

"It is undisputed that the parties’ respective damages claims will be resolved through arbitration, but this Court is the proper venue for CytoDyn’s equitable claims pending arbitration."

Damages against Amarex for harm to Cytodyn clinical trial program and business reputation could result in enormous monetary damages paid to Cytodyn.

I find James argument compelling (James is a trial attorney with over 30 years of experience) that parties are in process of negotiating a settlement. His comments on ymb quoted below.

James
16 hours ago

“This is nothing more than an extension of time of the deadlines while negotiations take place. The NSF dismissal is proper as the events took place prior to the purchase of Amarex by NSF. Even then the dismissal is WITHOUT prejudice meaning other claims may be brought depending on what is found in the future. Sidley would never let the “deep pocket” off the hook voluntarily if they did not already have a deal worked out in principle with Amarex. Sidley has most likely advised CYDY to make a total settlement of claims because nobody wins in litigation. This goes along with what I said when the CC was canceled. Both parties need more time to sort through everything. This definitely isn't about CYDY’s supposed inability to post the bond. If that were the case then Amarex would not agree to delay the deadline. Lawyers do not want to be hurried. The lead Defense lawyer just withdrew and new counsel is either getting up to speed or handling a settlement. The fact that this is a joint motion to the court indicates the parties are working towards resolution. Notice no request to change the other hearing date set for 2/23? Everyone can stop with the bull about CYDY not having money to pay the bond. A bond is 10% of the base price. CYDY probably wanted to delay having to pay the 10% if negotiations are moving forward. So the delay saves CYDY $650k in wasted bond cost if negotiations are successfully completed. Understand lawyers…they want settlement…trials are always risky…getting 60% of what you want by settling instead of trying for 100% is in the client’s best interest sometimes. And if Amarex has nothing to hide they would never agree to postpone the deadlines. They would want the cloud over their head removed ASAP and do everything to force CYDY to post the bond and carry out the Order. All in all…this is about what I predicted Thursday. Settlement negotiations are under way and both sides agreed to extend the deadlines by joint motion so as allow negotiations to move forward. Settlement to be announced soon.

James
13 hours ago

Fair point…having not read every damn page of the 10K or whatever it is called…I was unaware the Court required a full cash bond. Doesn’t change anything…if CYDY couldn’t post the bond why would Amarex let them off the hook and file a JOINT motion extending deadlines? They wouldn’t. But you still don't post the bond until trial is your only option. And CYDY did have sufficient cash to post it per your own bashing posts!! That is irrelevant to my posting that settlement negotiations are clearly underway. You guys have no idea the power of a law firm like Sidley & Austin…they are never going to allow CYDY to lose this case against Amarex…CYDY holds ALL the cards…snd as stated earlier…the JOINT motion says it all in the legal world…inability to post the bond would have been shoved up CYDY’s butt by Amarex’ lawyers…at this level these lawyers are “killers”…I don’t claim to be at that level but I have seen it up close…the best move NP made was hiring Sidley…I reiterate…settlement negotiations are underway and a settlement will be announced soon…and then CYDY won’t have to post a bond and most likely will have cash paid to them as well.
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 69

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 129

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 40

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

Updated Category News Views 267

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 281

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 172

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
HiTHIUM Joins Cambridge to Boost Global Energy Storage

Updated Category News Views 288

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Continue Reading
Beko Pushes for Policy Synergy Amidst Carbon Shakeup

Updated Category News Views 166

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Continue Reading

Top 5 Most Recently Viewed Articles

BioXcel Therapeutics Secures Grant for BXCL501 Study in Stress Relief

Updated Category News Views 56

Exciting Development in Mental Health Treatment In a groundbreaking collaboration, BioXcel Therapeutics, Inc. (NASDAQ: BTAI) has joined forces with the University of North Carolina at Chapel Hill (UNC) thanks to a substantial grant from the U.S. Department of Defense. This grant aims to explore the effectiveness and safety of BXCL501, a novel treatment for acute stress...

Continue Reading
Eastern Michigan University Alumni Lead Research on Urban Wildlife

Updated Category News Views 197

Alumni Champions of Environmental Research In a remarkable tale of collaboration fueled by a shared passion for wildlife research, Eastern Michigan University alumni Dorothy Zahor and Kenneth Glynn came together to explore environmental issues through the lens of urban wildlife. Their dedication to the study of American robins has revealed fascinating insights into how...

Continue Reading
Verkada Appoints Micah Deriso to Strengthen Global Channel

Updated Category News Views 157

Verkada Strengthens Global Channel Operations Verkada, known for its innovative cloud-based physical security solutions, recently announced a strategic enhancement in its global channel operations with the appointment of Micah Deriso as Head of Global Channel. This strategic move aims to bolster Verkada's global partnerships and streamline its channel strategy. Meet Micah...

Continue Reading
Investigation Launched into Citi Trends, Inc. by Purcell & Lefkowitz

Updated Category News Views 211

Purcell & Lefkowitz LLP Investigates Citi Trends, Inc. Recently, Purcell & Lefkowitz LLP announced an investigation concerning Citi Trends, Inc. (NASDAQ: CTRN). This inquiry arises from concerns regarding the fiduciary duties of the directors amidst ongoing corporate actions. The aim is to determine if there have been any breaches that may affect shareholders....

Continue Reading
Prairie Operating Co. Advances with Shelduck South Pad Success

Updated Category News Views 125

Prairie Operating Co. Announces Successful Shelduck South Pad Completion Prairie Operating Co. (Nasdaq: PROP) has recently achieved a remarkable milestone with the timely completion of its Shelduck South pad in the DJ Basin. This accomplishment marks the successful culmination of the first phase of its development program for 2025, aiming for all production to be fully...

Continue Reading